# Are Diabetics Clinically Vulnerable? A Comprehensive Analysis

## Introduction

Diabetes mellitus, encompassing primarily type 1 (T1D) and type 2 diabetes (T2D), is a chronic metabolic disorder with a growing global prevalence. As of 2021, approximately 10.5% of the global population (536.6 million people) and 11.6% of individuals in the United States (38.4 million people) live with diabetes ([BMC Public Health, 2025](https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-025-22627-1)). The question of whether diabetics are clinically vulnerable—particularly in the context of infectious diseases such as COVID-19 and other health complications—has gained critical importance. This report aims to provide a detailed, evidence-based, and objective assessment of the clinical vulnerability of people with diabetes, drawing on recent guidelines, epidemiological data, and research findings.

---

## Defining Clinical Vulnerability in Diabetes

Clinical vulnerability refers to an increased risk of adverse health outcomes, including severe illness, complications, and mortality, due to underlying medical conditions. For diabetes, vulnerability is multifactorial, influenced by glycemic control, comorbidities, social determinants of health (SDOH), and the presence of diabetes-related complications.

The UK-based organization IDDT clarifies that having diabetes alone does not automatically categorize a person as clinically vulnerable; rather, clinical vulnerability applies to those with additional risk factors or who have been specifically identified by healthcare providers or public health authorities ([IDDT, 2021](https://www.iddt.org/who-is-classed-as-clinically-vulnerable/)). This nuanced understanding is crucial for targeted clinical and public health interventions.

---

## Evidence of Clinical Vulnerability in Diabetics

### 1. Increased Risk of Severe COVID-19 Outcomes

A landmark prospective, community-based study (iNPHORM) involving 1,206 Americans with type 1 or type 2 diabetes found that people with diabetes are at heightened risk for COVID-19 infection and severe outcomes. The study identified multiple risk factors for COVID-19 contraction, including obesity (BMI ≥30 kg/m²), poor glycemic control (A1C ≥9.1% or ≤7%), comorbidities, and employment status ([McKay et al., 2022](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258990/)). Notably, diabetes ranked as the second most common underlying condition among U.S. COVID-19 cases, contributing to higher morbidity, mortality, and long COVID prevalence.

The study also highlighted that tight glycemic control (A1C ≤7%) might paradoxically increase infection risk due to hypoglycemia-induced immune suppression, emphasizing the complexity of diabetes management during pandemics. These findings underscore that diabetics, particularly those with poor metabolic control or obesity, are clinically vulnerable to infectious diseases ([McKay et al., 2022](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258990/)).

### 2. Diabetes-Related Complications and Comorbidities

Diabetes is associated with multiple chronic complications, including diabetic nephropathy, retinopathy, neuropathy, cardiovascular disease, and metabolic syndrome. These conditions contribute to increased clinical vulnerability by impairing organ function and immune responses ([Hua, 2020](https://pmc.ncbi.nlm.nih.gov/articles/PMC7812242/)).

Furthermore, diabetes often coexists with obesity, hypertension, and nonalcoholic fatty liver disease (NAFLD), which exacerbate health risks. The American Diabetes Association (ADA) 2025 Standards of Care emphasize the importance of addressing these comorbidities to reduce cardiovascular and kidney disease risks ([ADA, 2024](https://diabetes.org/newsroom/press-releases/american-diabetes-association-releases-standards-care-diabetes-2025)).

### 3. Social Determinants of Health (SDOH) and Vulnerability

Emerging evidence highlights that social determinants—such as socioeconomic status (SES), education, occupation, and community resources—play a critical role in diabetes outcomes. Lower SES correlates with higher diabetes prevalence, poorer glycemic control, and increased mortality ([Lenzi & Filardi, 2023](https://link.springer.com/article/10.1007/s40618-022-01952-x)).

Social vulnerability, measured by indices like the CDC’s Social Vulnerability Index (SVI), predicts adverse diabetes outcomes, including symptom burden and attrition from management programs ([BMC Public Health, 2025](https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-025-22627-1)). These non-clinical factors compound clinical vulnerability and necessitate integrated care approaches.

---

## Clinical Guidelines and Recognition of Vulnerability

### ADA Standards of Care 2025

The ADA’s 2025 Standards of Care explicitly recognize the heterogeneity of diabetes and the need for personalized care. They include:

- **Screening for psychological distress** such as fear of hypoglycemia and diabetes-related anxiety, which can affect management adherence.
- **Guidance on medication use** during shortages and continuation of weight management pharmacotherapy beyond weight loss goals.
- **Recommendations for antibody-based screening** for presymptomatic type 1 diabetes in high-risk individuals ([ADA, 2024](https://diabetes.org/newsroom/press-releases/american-diabetes-association-releases-standards-care-diabetes-2025)).
- **Emphasis on nutrition and lifestyle** interventions tailored to individual metabolic goals and social contexts.

These guidelines reflect an understanding of clinical vulnerability as a dynamic state influenced by biological, psychological, and social factors.

### Recognition by Public Health Authorities

During the COVID-19 pandemic, public health authorities identified people with diabetes, especially those with poorly controlled disease or multiple comorbidities, as clinically vulnerable groups requiring shielding or prioritized vaccination ([IDDT, 2021](https://www.iddt.org/news/news-releases/clinically-vulnerable-and-shielding/)).

---

## Implications for Clinical Practice and Public Health

### Targeted Interventions

Given the evidence, diabetics—particularly those with poor glycemic control, obesity, comorbidities, or social vulnerabilities—should be considered clinically vulnerable. This classification justifies prioritizing these individuals for:

- Enhanced monitoring and individualized care plans.
- Access to advanced therapies such as GLP-1 receptor agonists for cardiovascular and renal protection ([NIDDK, 2024](https://www.niddk.nih.gov/health-information/professionals/diabetes-discoveries-practice/changes-standards-care-diabetes2025)).
- Psychosocial support to address diabetes distress and improve adherence.
- Public health measures including vaccination, infection prevention, and community-based self-management programs.

### Addressing Social Vulnerabilities

Interventions must integrate social determinants by:

- Utilizing community resources to support vulnerable populations.
- Implementing culturally sensitive education and support programs.
- Reducing barriers to healthcare access and medication adherence ([BMC Public Health, 2025](https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-025-22627-1)).

---

## Conclusion

Based on current evidence and authoritative guidelines, people with diabetes—especially those with suboptimal glycemic control, obesity, comorbid conditions, and social vulnerabilities—are clinically vulnerable. This vulnerability manifests as increased risks for severe infectious diseases (notably COVID-19), diabetes-related complications, and poorer overall health outcomes.

However, diabetes alone does not universally confer clinical vulnerability; rather, it is the interplay of metabolic control, comorbidities, and social determinants that defines the risk profile. Recognizing this complexity is essential for clinicians and public health practitioners to implement targeted, equitable, and effective interventions.

Thus, the clinical vulnerability of diabetics should be acknowledged in a stratified manner, with priority given to those at highest risk, ensuring optimized care and resource allocation to improve health outcomes.

---

## References

American Diabetes Association. (2024, December 9). *The American Diabetes Association Releases Standards of Care in Diabetes—2025*. American Diabetes Association. https://diabetes.org/newsroom/press-releases/american-diabetes-association-releases-standards-care-diabetes-2025

BMC Public Health. (2025). *Community-based diabetes self-management and support program: addressing quality of life and social vulnerability*. https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-025-22627-1

Hua, F. (2020). New insights into diabetes mellitus and its complications: a narrative review. *Annals of Translational Medicine*, 8(24), 1689. https://pmc.ncbi.nlm.nih.gov/articles/PMC7812242/

IDDT. (2021). *Who is classed as ‘clinically vulnerable’?* https://www.iddt.org/who-is-classed-as-clinically-vulnerable/

IDDT. (2021). *‘Clinically vulnerable’ and shielding*. https://www.iddt.org/news/news-releases/clinically-vulnerable-and-shielding/

Lenzi, F. R., & Filardi, T. (2023). Social determinants of vulnerabilities in type 2 diabetes: a call to action. *Journal of Endocrinological Investigation*, 46(4), 841–844. https://link.springer.com/article/10.1007/s40618-022-01952-x

McKay, A., et al. (2022). Real‐world risk factors of confirmed or probable COVID‐19 in Americans with diabetes: A prospective, community‐based study (iNPHORM). *Diabetes, Obesity and Metabolism*, 24(4), 789-799. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258990/

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). (2024). *Changes to the Standards of Care in Diabetes—2025*. https://www.niddk.nih.gov/health-information/professionals/diabetes-discoveries-practice/changes-standards-care-diabetes2025

---

*Report prepared on April 25, 2025.*